ARZNEIWERK AG VIDA (TLIK.DE) Stock Fundamental Analysis

FRA:TLIK • DE000A289B07

0.585 EUR
+0.08 (+17%)
Last: Jun 27, 2025, 07:00 PM
Fundamental Rating

1

TLIK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 32 industry peers in the Health Care Providers & Services industry. TLIK may be in some trouble as it scores bad on both profitability and health. TLIK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TLIK had negative earnings in the past year.
  • TLIK had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TLIK reported negative net income in multiple years.
  • In multiple years TLIK reported negative operating cash flow during the last 5 years.
TLIK.DE Yearly Net Income VS EBIT VS OCF VS FCFTLIK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of TLIK (-18.11%) is worse than 92.00% of its industry peers.
Industry RankSector Rank
ROA -18.11%
ROE N/A
ROIC N/A
ROA(3y)-50.09%
ROA(5y)11.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLIK.DE Yearly ROA, ROE, ROICTLIK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K 2K

1.3 Margins

  • TLIK has a worse Gross Margin (6.17%) than 80.00% of its industry peers.
  • TLIK's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TLIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-59.12%
GM growth 5Y-38.57%
TLIK.DE Yearly Profit, Operating, Gross MarginsTLIK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100

0

2. Health

2.1 Basic Checks

  • TLIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TLIK has about the same amout of shares outstanding than it did 1 year ago.
  • TLIK has a worse debt/assets ratio than last year.
TLIK.DE Yearly Shares OutstandingTLIK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
TLIK.DE Yearly Total Debt VS Total AssetsTLIK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

2.2 Solvency

  • TLIK has an Altman-Z score of 1.19. This is a bad value and indicates that TLIK is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.19, TLIK is in line with its industry, outperforming 44.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACCN/A
WACC4.48%
TLIK.DE Yearly LT Debt VS Equity VS FCFTLIK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

  • TLIK has a Current Ratio of 0.63. This is a bad value and indicates that TLIK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of TLIK (0.63) is worse than 72.00% of its industry peers.
  • A Quick Ratio of 0.26 indicates that TLIK may have some problems paying its short term obligations.
  • The Quick ratio of TLIK (0.26) is worse than 92.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.26
TLIK.DE Yearly Current Assets VS Current LiabilitesTLIK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

3

3. Growth

3.1 Past

  • TLIK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.64%, which is quite impressive.
  • TLIK shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.21%.
  • The Revenue has been growing by 62.08% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.14%
Revenue 1Y (TTM)-19.21%
Revenue growth 3Y176.64%
Revenue growth 5Y62.08%
Sales Q2Q%-0.22%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLIK.DE Yearly Revenue VS EstimatesTLIK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TLIK. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLIK.DE Price Earnings VS Forward Price EarningsTLIK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLIK.DE Per share dataTLIK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • TLIK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ARZNEIWERK AG VIDA

FRA:TLIK (6/27/2025, 7:00:00 PM)

0.585

+0.08 (+17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-26
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners34.31%
Ins Owner ChangeN/A
Market Cap3.64M
Revenue(TTM)59.68M
Net Income(TTM)-2.20M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS9.58
BVpS-0.8
TBVpS-0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 6.17%
FCFM N/A
ROA(3y)-50.09%
ROA(5y)11.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-59.12%
GM growth 5Y-38.57%
F-Score2
Asset Turnover4.91
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.65%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.26
Altman-Z 1.19
F-Score2
WACC4.48%
ROIC/WACCN/A
Cap/Depr(3y)64.75%
Cap/Depr(5y)48.85%
Cap/Sales(3y)1.25%
Cap/Sales(5y)0.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.14%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.21%
Revenue growth 3Y176.64%
Revenue growth 5Y62.08%
Sales Q2Q%-0.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-102.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-109.91%
OCF growth 3YN/A
OCF growth 5YN/A

ARZNEIWERK AG VIDA / TLIK.DE FAQ

Can you provide the ChartMill fundamental rating for ARZNEIWERK AG VIDA?

ChartMill assigns a fundamental rating of 1 / 10 to TLIK.DE.


What is the valuation status for TLIK stock?

ChartMill assigns a valuation rating of 0 / 10 to ARZNEIWERK AG VIDA (TLIK.DE). This can be considered as Overvalued.


What is the profitability of TLIK stock?

ARZNEIWERK AG VIDA (TLIK.DE) has a profitability rating of 1 / 10.